Modifications of surfactant phospholipid pattern in premature infants treated with curosurf: clinical and dietary correlations.

Reduced mortality in small premature infants treated at birth with a single dose of synthetic surfactant.

Exogenous surfactant therapy for premature infants.

Respiratory compliance in premature babies treated with artificial surfactant (ALEC).

Retinopathy of prematurity in surfactant treated infants.

Follow up of premature babies treated with artificial surfactant (ALEC).

Pulmonary mechanics in premature infants one month after treatment with synthetic surfactant.

Surfactant treatment for premature babies--a review of clinical trials.

Phospholipid and surfactant protein A concentrations in tracheal aspirates from infants requiring extracorporeal membrane oxygenation.

Plasma lecithin-cholesterol acyltransferase activity and cholesterol and phospholipid levels in premature newborn infants.

Pulmonary mechanics and energetics in preterm infants who had respiratory distress syndrome treated with synthetic surfactant.

Surfactant protein A, phosphatidylcholine, and surfactant inhibitors in epithelial lining fluid. Correlation with surface activity, severity of respiratory distress syndrome, and outcome in small premature infants.

[Surfactant substitution in severe respiratory distress syndrome in premature infants weighing less than 1,000 g].

Enteropathogenic Esch. coli gastroenteritis in premature infants and children treated with fosfomycin.

Hormonal correlations of premature ejaculation.

Surfactant protein-D-encoding gene variant polymorphisms are linked to respiratory outcome in premature infants.

Results of laboratory surveillance of very low birth weight infants treated with a synthetic surfactant.

Phagocytic functions and tumor necrosis factor secretion of human monocytes exposed to natural porcine surfactant (Curosurf).

Exogenous porcine surfactant (Curosurf) is inactivated by monoclonal antibody to the surfactant-associated hydrophobic protein SP-B.

Applications of anti-curosurf antibodies to understanding the biology of alveolar surfactant.

A multicenter, randomized, double-blind trial of a new porcine surfactant in premature infants with respiratory distress syndrome.

Decreased mortality rate among small premature infants treated at birth with a single dose of synthetic surfactant: a multicenter controlled trial. American Exosurf Pediatric Study Group 1.

Analysis of the cost-effectiveness of surfactant treatment (Curosurf®) in respiratory distress syndrome therapy in preterm infants: early treatment compared to late treatment.

Epidurography in premature infants.

Temperament of premature infants with cerebral palsy.

Suggest Documents

Reduced mortality in small premature infants treated at birth with a single dose of synthetic surfactant.

Exogenous surfactant therapy for premature infants.

Respiratory compliance in premature babies treated with artificial surfactant (ALEC).

Retinopathy of prematurity in surfactant treated infants.

Follow up of premature babies treated with artificial surfactant (ALEC).

Pulmonary mechanics in premature infants one month after treatment with synthetic surfactant.

Surfactant treatment for premature babies--a review of clinical trials.

Phospholipid and surfactant protein A concentrations in tracheal aspirates from infants requiring extracorporeal membrane oxygenation.

Plasma lecithin-cholesterol acyltransferase activity and cholesterol and phospholipid levels in premature newborn infants.

Pulmonary mechanics and energetics in preterm infants who had respiratory distress syndrome treated with synthetic surfactant.

Surfactant protein A, phosphatidylcholine, and surfactant inhibitors in epithelial lining fluid. Correlation with surface activity, severity of respiratory distress syndrome, and outcome in small premature infants.

[Surfactant substitution in severe respiratory distress syndrome in premature infants weighing less than 1,000 g].

Enteropathogenic Esch. coli gastroenteritis in premature infants and children treated with fosfomycin.

Hormonal correlations of premature ejaculation.

Surfactant protein-D-encoding gene variant polymorphisms are linked to respiratory outcome in premature infants.

Results of laboratory surveillance of very low birth weight infants treated with a synthetic surfactant.

Phagocytic functions and tumor necrosis factor secretion of human monocytes exposed to natural porcine surfactant (Curosurf).

Exogenous porcine surfactant (Curosurf) is inactivated by monoclonal antibody to the surfactant-associated hydrophobic protein SP-B.

Applications of anti-curosurf antibodies to understanding the biology of alveolar surfactant.

A multicenter, randomized, double-blind trial of a new porcine surfactant in premature infants with respiratory distress syndrome.

Decreased mortality rate among small premature infants treated at birth with a single dose of synthetic surfactant: a multicenter controlled trial. American Exosurf Pediatric Study Group 1.

Analysis of the cost-effectiveness of surfactant treatment (Curosurf®) in respiratory distress syndrome therapy in preterm infants: early treatment compared to late treatment.

Epidurography in premature infants.

Temperament of premature infants with cerebral palsy.

Modifications of surfactant phospholipid pattern in premature infants treated with curosurf: clinical and dietary correlations.

Recommend Documents

Follow Us